Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2026
    • The 2026 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2026 Leadership
    • 2025 Winners
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

PROTECT II Interim Results Demonstrate That Impella Is Not Superior to the Intra-Aortic Balloon Pump in Reducing Major Adverse Events in High Risk Patients Receiving Percutane…

December 9, 2010 By Bio-Medicine.Org

MAHWAH, N.J., Dec. 9, 2010 /PRNewswire/ — MAQUET
Cardiovascular, the leading distributor of intra-aortic balloon
pumps (IABP) worldwide, learned that the PROTECT II clinical trial,
sponsored by Abiomed, that compared the safety and effectiveness of
the Impella percutaneous ventricular assist device to intra-aortic
balloon pumping in elective high-risk percutaneous coronary
interventions (PCI) has been stopped.  The Data Safety
Monitoring Board determined, based on a review of the interim
results, that Impella would likely not show a statistical
difference in the rate of major adverse events compared to IABP at
the completion of the trial.  

The interim analysis of data from 305 patients, less than half
of the 654 planned patients targeted for enrollment, showed no
statistical difference in the rate of major adverse events, the
primary endpoint of the trial, which included, but was not limited
to, a difference in death, myocardial infarction and stroke between
Impella and the IABP treatment groups.  These results are
consistent with an article published by Washington Hospital Center
earlier this year, which questioned the clinical benefit of the
PROTECT II study in this high-risk cohort of patients.

According to George W. Christy, MD, of Advocate Health System,
Chicago, IL, “The trial did not meet the primary end-point and does
not support use of a more expensive device with potentially higher
complications over conventional and widely accepted IABP
therapy.”

“The trial speaks for itself – it did not meet the primary
end-point,” said Christian Keller, President and Chief Executive
Officer of MAQUET Cardiovascular.  “These results highlight
what many cardiologists and hospital administrators have known for
some time – IABP has been, and remains, the gold standard for
delivering the critical cardiac support patients need in a way that
also makes economic sense for the hospital.”

About MAQUET IABP<

‘/>”/>

SOURCE

Related Articles Read More >

An illustration showing the Autus size-adjustable heart valve being expanded years after implantation with a minimally invasive balloon catheter.
The first-of-its-kind Autus pediatric heart valve is designed for expansion and durability
The MIT researcher's implant, LUCID.
MIT researchers design implantable ultrasound-powered drug delivery device to minimize tumor recurrence
An image of the Teleflex Freesolve RMS resorbable magnesium scaffold.
Teleflex Interventional leader sees resorbables as ‘the next frontier’ of PCI
Feminai's breast sensor patch
AdvaMed and MedTech Innovator name 2026 prize winners and finalists
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2026 Arrowfly, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2026
    • The 2026 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2026 Leadership
    • 2025 Winners
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe